Study Finds Mescaline May Trigger Improvements in Psychiatric Symptoms

July 15, 2021 12:35:59

An exploratory study that was recently published in the “ACS Pharmacology and Translational Science” journal has found that using mescaline has been linked to improvements in anxiety and depression. Mescaline is a psychedelic hallucinogen derived from the peyote cactus. This study provides evidence that some of the useful effects of mescaline are associated with certain facets of the psychedelic experience.

Prior research suggests that the use of classic psychedelics may have long-term positive effects. However, the use of mescaline among Native American tribes hasn’t received as much attention as other substances, such as psilocybin.

In the study, the researchers note that present-day research on classic psychedelics has demonstrated the potential they possess for treating various mental health conditions, including addiction, PTSD, distress related to a severe ailment and major depressive disorder. Researchers add that the psychiatric benefits of some classic psychedelics, such as psilocybin, have been well researched in the recent past, which has facilitated further research into other psychedelics.

For their research, the team recruited more than 400 grown-ups who had used mescaline. Each participant completed a questionnaire about their experience with the substance, after which they underwent a mental health evaluation in which they were asked to report any symptoms of drug use or drug misuse disorder, alcohol use or alcohol misuse disorder, post-traumatic stress disorder, anxiety and depression.

Of the participants, roughly one-third admitted that their experiences with mescaline had been spiritually significant or personally meaningful, with a good number also reporting that they had seen improvements in psychiatric disorders after its use. Almost half of the participants also revealed that they felt anxiety or depression when they used the psychedelic. More than 80% of those who had depression admitted to seeing improvements in their condition after they’d used the substance. Likewise, 80% of the participants who suffered from anxiety also saw improvements in their condition after using the drug.

The researchers assert that the majority of the participants didn’t consume mescaline with the aim of changing their disorder. They also discovered that psychiatric improvement was linked to certain features of the psychedelic experience. In particular, participants who recorded improvements were more inclined to experience increased ego dissolution effects and mystical-type phenomena as well as greater psychological insight while under the influence of the psychedelic substance.

The study’s findings align with prior research that showed evidence that experiencing psychological insights from psychedelic substances was linked to increased psychological flexibility.

Mescaline isn’t the only psychedelic compound found to hold promise as a treatment for mental health problems. Other companies, including Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), are looking into other compounds such as psilocybin, for which dozens of studies have established their potential as possible treatments for psychiatric disorders.

NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office